The Association Between Hepatitis C Virus and HIV-1 in Preparatory Cohorts for HIV Vaccine Trials in Thailand
Overview
Authors
Affiliations
Objectives: To study the association between hepatitis C virus (HCV) and HIV-1, and HCV seropositivity as an indicator of HIV-1 risk behavior for HIV vaccine preparatory cohorts in Thailand.
Design: Cross-sectional study of HIV-1-infected persons identified at screening for potential HIV vaccine trial cohort studies.
Methods: Sera from HIV-1-infected and uninfected volunteers was matched by age, sex, and community, and tested for HCV reactivity. Logistic regression methods were used to measure associations between HIV-1, HCV and other risk factors for HIV infection.
Results: The prevalence of HCV among HIV-negative controls was 8.3% (6/72) for men and 4.2% (5/118) for women. Co-infection with HIV and occurred in 50.7% (37/73) of men and 3.4% (4/118) of women. Among men who reported injection drug use (IDU), 96.4% (27/28) were HCV seropositive. No women reported IDU. HCV was associated with HIV infection [odds ratio (OR), 11.3; 95% confidence interval (CI), 4.4-29.3] and IDU (OR, 12.0; 95% CI, 3.4-41.9) among men, but not women (OR, 0.8; 95% CI, 0.2-3.0). After adjustment for potential confounding, HCV, but not IDU, remained strongly associated with HIV-1 infection among men (OR, 9.4; 95% CI, 2.7-32.6).
Conclusions: The strong associations between HCV seropositivity, HIV-1 infection, and IDU history suggest that IDU was reported accurately in this study. The surprisingly high prevalence of HCV among HIV-1-infected young men may assist health policy makers in the choice of behavioral interventions for this important subgroup of the population.
Paul R, Shikuma C, Vinh Chau N, Ndhlovu L, Thanh N, Belden A Front Neurol. 2021; 12:602263.
PMID: 33776879 PMC: 7996090. DOI: 10.3389/fneur.2021.602263.
Prevalence and risk factors for hepatitis C virus infection among young Thai men.
Jatapai A, Nelson K, Chuenchitra T, Kana K, Eiumtrakul S, Sunantarod E Am J Trop Med Hyg. 2010; 83(2):433-9.
PMID: 20682895 PMC: 2911198. DOI: 10.4269/ajtmh.2010.09-0749.
Ngo-Giang-Huong N, Jourdain G, Sirirungsi W, Decker L, Khamduang W, Le Coeur S Int J Infect Dis. 2010; 14(7):e602-7.
PMID: 20047847 PMC: 2886172. DOI: 10.1016/j.ijid.2009.09.002.
The potential role of biomarkers in HIV preventive vaccine trials.
MacLachlan E, Mayer K, Barnabas R, Sanchez J, Koblin B, Duerr A J Acquir Immune Defic Syndr. 2009; 51(5):536-45.
PMID: 19512938 PMC: 2920071. DOI: 10.1097/QAI.0b013e3181adcbbe.
Ruan Y, Hong K, Liu S, He Y, Zhou F, Qin G World J Gastroenterol. 2004; 10(11):1589-93.
PMID: 15162531 PMC: 4572760. DOI: 10.3748/wjg.v10.i11.1589.